Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985) is a research paper published in European Journal of Medicinal Chemistry (2019). On theSindex it has a DataRank of 5.4. It has been cited 171 times, with 166 citing works in its 1-hop citation network.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.772
From this paper's citation signal
Citation Network Contribution
4.6
From 139 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 166 citers.
Chengdu Science and Technology Program
Grant: 2015-HM01-00463-SF
Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital Foundation
Grant: 2016QN08
Sichuan Science and Technology Program
Grant: 2018SZ0169
Health Commission of Sichuan Province
Grant: 150229
FWCI
6.35
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals